The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer
Published version of a preprint
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer characterized by activating KRAS mutations and TP53 alterations. TP53 missense mutations lose their wild-type tumor-suppressor function. Here, we studied whether p53 missense mutations have potential gain-of-function oncogenic roles and their impact on cancer-cell-intrinsic gene expression and the tumor immune microenvironment (TME) in PDAC. p53 R172H established an immunosuppressive TME and impaired the efficacy of immune checkpoint inhibitors (ICIs) by regulating a distinct set of chemokines. Among these, tumor-specific reduction of Cxcl1 , which encodes a chemoattractant for neutrophils, promoted T cell infiltration and decreased tumor growth. Mechanistically, p53 R172H occupied the distal enhancers of Cxcl1 and amplified its expression. These enhancers were responsible for Cxcl1 expression and were essential for its immunosuppressive function. Nuclear factor κB (NF-κB) was a critical cofactor required for p53 R172H occupancy at these enhancers. Thus, a common mutation in a tumor-suppressor transcription factor appropriates enhancers, thereby stimulating chemokine expression and establishing an immunosuppressive TME that diminishes ICI efficacy in PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further, TP53 is an essential regulator for cytokine expression in tumor cells 38-40, actively reshaping the profile of cytokines and chemokines secreted by cancer cells in vitro and in vivo.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [39]
In the citing paper
“Interestingly, single TP53 mutations can also upregulate target genes (e.g., CXCL1, MDR1) by increasing enhancer activity or through cofactor-mediated promoter binding 39.”
From Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer (2026) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
QuPath: Open source software for digital pathology image analysis
Bankhead, P., Loughrey, M. B., Fernández, J. A., Dombrowski, Y., McArt, D. G., Dunne, P. D., McQuaid, S., Gray, R. T., Murray, L. J., Coleman, H. G., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17204-5 · Cited by 8,908
KEGG for taxonomy-based analysis of pathways and genomes
Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M., & Ishiguro-Watanabe, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac963 · Cited by 5,833
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551
Widespread transcription at neuronal activity-regulated enhancers
Kim, T.-K., Hemberg, M., Gray, J. M., Costa, A. M., Bear, D. M., Wu, J., Harmin, D. A., Laptewicz, M., Barbara-Haley, K., Kuersten, S., et al. (2010) · Nature · doi:10.1038/nature09033 · Cited by 2,450
Integrated genomic characterization of pancreatic ductal adenocarcinoma
Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Research works printed but not linked: 106
- Park, 2021, Pancreatic Cancer: A Review, JAMA, 326, 851, 10.1001/jama.2021.13027 · DOI · Paper page
- Royal, 2010, Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma, J. Immunother., 33, 828, 10.1097/CJI.0b013e3181eec14c · DOI · Paper page
- Sharma, 2018, Efficacy and tolerability of tremelimumab in patients with metastatic pancreatic ductal adenocarcinoma, J. Clin. Oncol., 36, 470, 10.1200/JCO.2018.36.4_suppl.470 · DOI
- O’Reilly, 2019, Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial, JAMA Oncol., 5, 1431, 10.1001/jamaoncol.2019.1588 · DOI · Paper page
- Brahmer, 2012, Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694 · DOI · Paper page
- Zheng, 2024, Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application, Front. Immunol., 15, 10.3389/fimmu.2024.1383978 · DOI
- Kaufman, 2015, Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation, J. Clin. Oncol., 33, 244, 10.1200/JCO.2014.56.2728 · DOI · Paper page
- Higuchi, 2015, CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer, Cancer Immunol. Res., 3, 1257, 10.1158/2326-6066.CIR-15-0044 · DOI · Paper page
- Reiss, 2022, Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial, Lancet Oncol., 23, 1009, 10.1016/S1470-2045(22)00369-2 · DOI
- Hidalgo, 2019, A Multi-Center Phase IIA Trial to Assess the Safety and Efficacy of BL-8040 (a CXCR4 Inhibitor) in Combination with Pembrolizumab and Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC), Ann. Oncol., 30, 10.1093/annonc/mdz451 · DOI
- Zemek, 2019, Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment, Sci. Transl. Med., 11, 10.1126/scitranslmed.aav7816 · DOI · Paper page
- Aggarwal, 2023, First-in-class oral innate immune activator BXCL701 combined with pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) phenotype: Phase 2a final results, J. Clin. Oncol., 41, 10.1200/JCO.2023.41.6_suppl.176 · doi:10.1200/jco.2023.41.6_suppl.176
- Zhu, 2015, Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth, Nature, 525, 206, 10.1038/nature15251 · DOI · Paper page
- Wang, 2024, Loss-of-Function but Not Gain-of-Function Properties of Mutant TP53 Are Critical for the Proliferation, Survival, and Metastasis of a Broad Range of Cancer Cells, Cancer Discov., 14, 362, 10.1158/2159-8290.CD-23-0402 · DOI · Paper page
- Willis, 2004, Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes, Oncogene, 23, 2330, 10.1038/sj.onc.1207396 · DOI · Paper page
- Shaulsky, 1991, Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins, Cancer Res., 51, 5232
- Cooks, 2013, Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer, Cancer Cell, 23, 634, 10.1016/j.ccr.2013.03.022 · DOI · Paper page
- Alexandrova, 2015, Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment, Nature, 523, 352, 10.1038/nature14430 · DOI · Paper page
- Alexandrova, 2017, p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo, Cell Death Dis., 8, 10.1038/cddis.2017.80 · DOI
- Hanel, 2013, Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis, Cell Death Differ., 20, 898, 10.1038/cdd.2013.17 · DOI · Paper page
- Xu, 2011, Gain of function of mutant p53 by coaggregation with multiple tumor suppressors, Nat. Chem. Biol., 7, 285, 10.1038/nchembio.546 · DOI · Paper page
- Kim, 2021, Oncogenic KRAS Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis, Cancer Discov., 11, 2094, 10.1158/2159-8290.CD-20-1228 · DOI · Paper page
- Inga, 2001, p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay, Oncogene, 20, 501, 10.1038/sj.onc.1204116 · DOI
- Adorno, 2009, A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis, Cell, 137, 87, 10.1016/j.cell.2009.01.039 · DOI · Paper page
- Mello, 2013, Not all p53 gain-of-function mutants are created equal, Cell Death Differ., 20, 855, 10.1038/cdd.2013.53 · DOI
- Amelio, 2020, Context is everything: extrinsic signalling and gain-of-function p53 mutants, Cell Death Discov., 6, 10.1038/s41420-020-0251-x · DOI
- Oren, 2024, p53: A tale of complexity and context, Cell, 187, 1569, 10.1016/j.cell.2024.02.043 · DOI
- Baugh, 2018, Why are there hotspot mutations in the TP53 gene in human cancers?, Cell Death Differ., 25, 154, 10.1038/cdd.2017.180 · DOI · Paper page
- Hassin, 2022, Different hotspot p53 mutants exert distinct phenotypes and predict outcome of colorectal cancer patients, Nat. Commun., 13, 10.1038/s41467-022-30481-7 · DOI
- Orth, 2019, Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches, Radiat. Oncol., 14, 10.1186/s13014-019-1345-6 · DOI · Paper page
- Maddalena, 2021, TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment, Proc. Natl. Acad. Sci. USA, 118, 10.1073/pnas.2025631118 · DOI
- Balsano, 2023, Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights, Curr. Oncol., 30, 3871, 10.3390/curroncol30040293 · DOI
- Koikawa, 2021, Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy, Cell, 184, 4753, 10.1016/j.cell.2021.07.020 · DOI · Paper page
- Siolas, 2021, Gain-of-function p53R172H mutation drives accumulation of neutrophils in pancreatic tumors, promoting resistance to immunotherapy, Cell Rep., 36, 10.1016/j.celrep.2021.109578 · DOI
- Terzian, 2008, The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss, Genes Dev., 22, 1337, 10.1101/gad.1662908 · DOI · Paper page
- Suh, 2011, Multiple Stress Signals Activate Mutant p53 In Vivo, Cancer Res., 71, 7168, 10.1158/0008-5472.CAN-11-0459 · DOI
- Sullivan, 2018, Mechanisms of transcriptional regulation by p53, Cell Death Differ., 25, 133, 10.1038/cdd.2017.174 · DOI · Paper page
- Zhang, 2017, Somatic super-enhancer duplications and hotspot mutations lead to oncogenic activation of the KLF5 transcription factor, Cancer Discov., 8
- Basil, 2022, Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities, Sci. Rep., 12, 10.1038/s41598-022-09371-x · DOI
- Chiang, 2021, The Function of the Mutant p53-R175H in Cancer, Cancers, 13, 10.3390/cancers13164088 · DOI
- Hingorani, 2005, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice, Cancer Cell, 7, 469, 10.1016/j.ccr.2005.04.023 · DOI · Paper page
- Donehower, 2019, Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas, Cell Rep., 28, 1370, 10.1016/j.celrep.2019.07.001 · DOI · Paper page
- Jacks, 1994, Tumor spectrum analysis in p53-mutant mice, Curr. Biol., 4, 1, 10.1016/S0960-9822(00)00002-6 · DOI · Paper page
- Gopinathan, 2015, GEMMs as preclinical models for testing pancreatic cancer therapies, Dis. Model. Mech., 8, 1185, 10.1242/dmm.021055 · DOI
- Morton, 2010, Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer, Proc. Natl. Acad. Sci. USA, 107, 246, 10.1073/pnas.0908428107 · DOI · Paper page
- Fischer, 2017, Census and evaluation of p53 target genes, Oncogene, 36, 3943, 10.1038/onc.2016.502 · DOI · Paper page
- Giuliano, 2014, The ELR+CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma, OncoImmunology, 3, 10.4161/onci.28399 · doi:10.4161/onci.28399
- Deng, 2021, Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance, Nat. Commun., 12, 10.1038/s41467-021-27349-7 · DOI
- Bardeesy, 2006, Both p16Ink4a and the p19Arf-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse, Proc. Natl. Acad. Sci. USA, 103, 5947, 10.1073/pnas.0601273103 · DOI · Paper page
- Peuget, 2024, Translating p53-based therapies for cancer into the clinic, Nat. Rev. Cancer, 24, 192, 10.1038/s41568-023-00658-3 · DOI · Paper page
- Parrales, 2015, Targeting Oncogenic Mutant p53 for Cancer Therapy, Front. Oncol., 5, 10.3389/fonc.2015.00288 · DOI · Paper page
- Sanford, 2013, Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis, Clin. Cancer Res., 19, 3404, 10.1158/1078-0432.CCR-13-0525 · DOI · Paper page
- Gschwandtner, 2019, More Than Just Attractive: How CCL2 Influences Myeloid Cell Behavior Beyond Chemotaxis, Front. Immunol., 10, 10.3389/fimmu.2019.02759 · DOI · Paper page
- Kalbasi, 2017, Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma, Clin. Cancer Res., 23, 137, 10.1158/1078-0432.CCR-16-0870 · DOI · Paper page
- Nywening, 2018, Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma, Gut, 67, 1112, 10.1136/gutjnl-2017-313738 · DOI · Paper page
- Metelitsa, 2004, Natural Killer T Cells Infiltrate Neuroblastomas Expressing the Chemokine CCL2, J. Exp. Med., 199, 1213, 10.1084/jem.20031462 · DOI · Paper page
- Korbecki, 2022, CXCL1: Gene, Promoter, Regulation of Expression, mRNA Stability, Regulation of Activity in the Intercellular Space, Int. J. Mol. Sci., 23, 10.3390/ijms23020792 · DOI
- Korbecki, 2022, CXCR2 Receptor: Regulation of Expression, Signal Transduction, and Involvement in Cancer, Int. J. Mol. Sci., 23, 10.3390/ijms23042168 · DOI · Paper page
- Fritz, 2022, Editorial: Innate lymphocytes in tumor surveillance, Front. Immunol., 13, 10.3389/fimmu.2022.1093318 · doi:10.3389/fimmu.2022.1093318
- Skene, 2017, An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites, eLife, 6, 10.7554/eLife.21856 · DOI · Paper page
- Mahat, 2016, Base-pair-resolution genome-wide mapping of active RNA polymerases using precision nuclear run-on (PRO-seq), Nat. Protoc., 11, 1455, 10.1038/nprot.2016.086 · DOI · Paper page
- Tippens, 2020, Transcription imparts architecture, function and logic to enhancer units, Nat. Genet., 52, 1067, 10.1038/s41588-020-0686-2 · DOI
- Danko, 2015, Identification of active transcriptional regulatory elements from GRO-seq data, Nat. Methods, 12, 433, 10.1038/nmeth.3329 · DOI · Paper page
- Morgan, 2020, Reevaluating the roles of histone-modifying enzymes and their associated chromatin modifications in transcriptional regulation, Nat. Genet., 52, 1271, 10.1038/s41588-020-00736-4 · DOI · Paper page
- Timofeev, 2019, Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses, EMBO J., 38, 10.15252/embj.2019102096 · DOI
- Resnick-Silverman, 2023, In vivo RNA-seq and ChIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity, Cell Rep., 42, 10.1016/j.celrep.2023.112216 · DOI
- Tesfaye, 2021, The p53 transcriptional response across tumor types reveals core and senescence-specific signatures modulated by long noncoding RNAs, Proc. Natl. Acad. Sci. USA, 118, 10.1073/pnas.2025539118 · DOI
- Liu, 2017, NF-κB signaling in inflammation, Signal Transduct. Target. Ther., 2
- Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
- Camacho, 2009, BLAST+: architecture and applications, BMC Bioinform., 10, 10.1186/1471-2105-10-421 · DOI · Paper page
- Rahnamoun, 2017, Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling, Nat. Commun., 8, 10.1038/s41467-017-01117-y · DOI
- Andrysik, 2017, Identification of a core TP53 transcriptional program with highly distributed tumor suppressive activity, Genome Res., 27, 1645, 10.1101/gr.220533.117 · DOI
- Lappalainen, 2021, From variant to function in human disease genetics, Science, 373, 1464, 10.1126/science.abi8207 · DOI · Paper page
- Korbecki, 2023, The Clinical Significance and Role of CXCL1 Chemokine in Gastrointestinal Cancers, Cells, 12, 10.3390/cells12101406 · DOI
- Yan, 2009, Identification of GRO1 as a Critical Determinant for Mutant p53 Gain of Function, J. Biol. Chem., 284, 12178, 10.1074/jbc.M900994200 · DOI
- Li, 2018, Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy, Immunity, 49, 178, 10.1016/j.immuni.2018.06.006 · DOI · Paper page
- Yang, 2021, Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity, Cancer Immunol. Res., 9, 200, 10.1158/2326-6066.CIR-20-0312 · DOI
- Aggarwal, 2011, NF-κB in Cancer: A Matter of Life and Death, Cancer Discov., 1, 469, 10.1158/2159-8290.CD-11-0260 · DOI · Paper page
- Dimitrakopoulos, 2020, The Fire Within: NF-κB Involvement in Non–Small Cell Lung Cancer, Cancer Res., 80, 4025, 10.1158/0008-5472.CAN-19-3578 · DOI
- Verzella, 2022, The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target, Biomedicines, 10, 10.3390/biomedicines10092233 · DOI
- Ahn, 2021, Phase separation drives aberrant chromatin looping and cancer development, Nature, 595, 591, 10.1038/s41586-021-03662-5 · DOI · Paper page
- Leroy, 2002, p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas, Ann. Oncol., 13, 1108, 10.1093/annonc/mdf185 · DOI
- Chen, 2022, Mutant p53 in cancer: from molecular mechanism to therapeutic modulation, Cell Death Dis., 13, 10.1038/s41419-022-05408-1 · DOI · Paper page
- Liu, 2011, Resuscitating Wild-Type p53 Expression by Disrupting Ceramide Glycosylation: A Novel Approach to Target Mutant p53 Tumors, Cancer Res., 71, 6295, 10.1158/0008-5472.CAN-11-0700 · DOI
- Duffy, 2022, Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?, Cancers, 14, 10.3390/cancers14184499 · DOI
- Gomes, 2021, Structural and Drug Targeting Insights on Mutant p53, Cancers, 13, 10.3390/cancers13133344 · DOI
- Hassin, 2023, Drugging p53 in cancer: one protein, many targets, Nat. Rev. Drug Discov., 22, 127, 10.1038/s41573-022-00571-8 · DOI · Paper page
- Freed-Pastor, 2012, Mutant p53: one name, many proteins, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Bianchi, 2023, Cell-autonomous Cxcl1 sustains tolerogenic circuitries and stromal inflammation via neutrophil-derived TNF in pancreatic cancer, Cancer Discov., 13, 1428, 10.1158/2159-8290.CD-22-1046 · DOI
- Man, 2022, High expression level of CXCL1/GROα is linked to advanced stage and worse survival in uterine cervical cancer and facilitates tumor cell malignant processes, BMC Cancer, 22, 10.1186/s12885-022-09749-0 · DOI
- Yu, 2019, CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer, Front. Oncol., 9
- Korbecki, 2023, Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive Cancers: Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer and Prostate Cancer, Int. J. Mol. Sci., 24, 10.3390/ijms24087262 · DOI
- Wang, 2018, CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-κB/SOX4 signaling, Cell Death Dis., 9
- Zhuo, 2022, CXCL1 promotes colon cancer progression through activation of NF-κB/P300 signaling pathway, Biol. Direct, 17, 10.1186/s13062-022-00348-4 · DOI
- Cao, 2014, Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma, Cancer Cell Int., 14, 10.1186/s12935-014-0086-8 · doi:10.1186/s12935-014-0086-8
- Hu, 2021, Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme, Sci. Adv., 7, 10.1126/sciadv.abc2511 · DOI
- Robinson, 2011, Integrative genomics viewer, Nat. Biotechnol., 29, 24, 10.1038/nbt.1754 · DOI · Paper page
- Schindelin, 2012, Fiji: an open-source platform for biological-image analysis, Nat. Methods, 9, 676, 10.1038/nmeth.2019 · DOI · Paper page
- Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol., 10, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
- Yu, 2012, clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters, OMICS A J. Integr. Biol., 16, 284, 10.1089/omi.2011.0118 · DOI · Paper page
- Chen, 2013, Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool, BMC Bioinform., 14, 10.1186/1471-2105-14-128 · DOI · Paper page
- Han, 2018, TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions, Nucleic Acids Res., 46, D380, 10.1093/nar/gkx1013 · DOI · Paper page
- Kent, 2002, The Human Genome Browser at UCSC, Genome Res., 12, 996, 10.1101/gr.229102 · DOI · Paper page
- Heinz, 2010, Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities, Mol. Cell, 38, 576, 10.1016/j.molcel.2010.05.004 · DOI · Paper page
- Li, 2009, The Sequence Alignment/Map format and SAMtools, Bioinformatics, 25, 2078, 10.1093/bioinformatics/btp352 · DOI · Paper page
- Martin-Rufino, 2023, Massively parallel base editing to map variant effects in human hematopoiesis, Cell, 186, 2456, 10.1016/j.cell.2023.03.035 · DOI
Cited by
Bian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
Metadata
- Authors
- Mahat, D. B., Kumra, H., Castro, S. A., Metcalf, E., Nguyen, K., Morisue, R., Ho, W. W., Chen, I., Sullivan, B., Yim, L. H., Singh, A., Fu, J., Waterton, S. K., Cheng, Y.-C., Moiso, E., Chauhan, V. P., Silva, H. M., Spranger, S., Jain, R. K., & Sharp, P. A.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2025-07
- Volume
- 58
- Issue
- 7
- Pages
- 1688-1705.e9
- ISSN
- 1074-7613
- Cited by
- 43
- References
- 25
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- GlaxoSmithKline
- Nile Albright Research Foundation
- Howard Hughes Medical Institute
- National Institutes of Health (R01-NS118929, R01-CA208205, R35-CA197743, U01-CA261842, U01-CA224348, R01-CA259253)
- Ragon Institute of MGH, MIT and Harvard
- Japan Society for the Promotion of Science
- Massachusetts General Hospital
- National Institutes of Health National Cancer Institute
- U.S. Public Health Service (R01-GM034277)
- National Foundation for Cancer Research (R00CA204595-05)
- Emerald Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.